| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-13 | ALKEON CAPITAL MANAGEMENT LLC | Keros Therapeutics, Inc. | 1,498,907 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Keros Therapeutics, Inc. | 3,874,204 | 12.9% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | Keros Therapeutics, Inc. | 2,036,788 | 6.8% | EDGAR |
| SC 13D/A | 2023-12-13 | ORBIMED ADVISORS LLC | Keros Therapeutics, Inc. | 1,268,734 | 4.2% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | Keros Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-13 | ALKEON CAPITAL MANAGEMENT LLC | Keros Therapeutics, Inc. | 1,392,402 | 5.1% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | Keros Therapeutics, Inc. | 3,679,089 | 13.4% | EDGAR |
| SC 13G/A | 2023-02-07 | BlackRock Inc. | Keros Therapeutics, Inc. | 1,638,326 | 5.9% | EDGAR |
| SC 13G/A | 2023-02-02 | Arkin Moshe | Keros Therapeutics, Inc. | 1,371,074 | 5.0% | EDGAR |
| SC 13D/A | 2022-11-07 | ORBIMED ADVISORS LLC | Keros Therapeutics, Inc. | 1,268,734 | 4.6% | EDGAR |
| SC 13G/A | 2022-04-12 | Arkin Moshe | Keros Therapeutics, Inc. | 1,812,315 | 7.6% | EDGAR |
| SC 13G | 2022-04-11 | Arkin Moshe | Keros Therapeutics, Inc. | 1,812,315 | 7.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Deep Track Capital, LP | Keros Therapeutics, Inc. | 1,300,000 | 5.5% | EDGAR |
| SC 13G/A | 2022-02-11 | Foresite Capital Fund IV, L.P. | Keros Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | Keros Therapeutics, Inc. | 3,504,798 | 15.0% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | Keros Therapeutics, Inc. | 1,286,526 | 5.5% | EDGAR |
| SC 13G | 2021-12-30 | Deep Track Capital, LP | Keros Therapeutics, Inc. | 1,288,724 | 5.4% | EDGAR |
| SC 13G/A | 2021-02-16 | Logos Global Master Fund LP | Keros Therapeutics, Inc. | 450,000 | 1.9% | EDGAR |
| SC 13G/A | 2021-02-16 | Foresite Capital Fund IV, L.P. | Keros Therapeutics, Inc. | 1,412,705 | 6.1% | EDGAR |
| SC 13G/A | 2021-02-10 | RA CAPITAL MANAGEMENT, L.P. | Keros Therapeutics, Inc. | 0 | 0.0% | EDGAR |